Calando, majority-owned by nanotechnology company Arrowhead, intends to develop non-viral RNAi delivery technologies licensed from the California Institute of Technology for therapeutic purposes. Caltech will receive an equity stake in exchange for the license.
Apart from Arrowhead, founders of Calando include Mark Davis, a professor of chemical engineering at Caltech; John Rossi, a molecular geneticist at the City of